Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Biostatistics, Yale University School of Medicine, New Haven, Connecticut, USA.
Diabet Med. 2023 Oct;40(10):e15123. doi: 10.1111/dme.15123. Epub 2023 May 10.
In youth with type 1 diabetes (T1D), high haemoglobin A1c (HbA1c) levels are associated with an increased risk for diabetic ketoacidosis (DKA).
This study examined whether daily school-supervised basal insulin injections were feasible and if they reduced the risk of morning ketosis in children and adolescents with high HbA1c levels. We hypothesized that supervised glargine and degludec would reduce the risk of ketosis and that the prolonged action of degludec would protect from ketosis after consecutive days of unsupervised injections.
MATERIALS & METHODS: After a 2-4-week run-in, youth (10-18 years, HbA1c ≥ 8.5%) managing T1D with injections were randomized to school-supervised administration of degludec or glargine for 4 months. School nurses observed daily blood β-hydroxybutyrate (BHB) and glucose checks. During COVID closures, the research team supervised procedures remotely.
Data from 28 youth (age 14.3 ± 2.3 years, HbA1c 11.4 ± 1.9%, 64% F) were analysed. School-supervised injections of both basal insulins for 1-4 days progressively lowered the percent of participants with elevated BHB. The percent of participants with elevated BHB (≥0.6 mmol/L) after 2 days of unsupervised basal insulin doses at home was greater in the glargine than degludec group but had a high p-value (17.2% vs. 9.0%, p = 0.3). HbA1c was unchanged in both groups.
In youth with T1D at high risk for DKA, daily supervised long-acting insulin administration decreased the probability of elevated ketone levels on subsequent school days, regardless of basal insulin type. A larger sample size may have demonstrated that the longer action profile of degludec would offer additional protection from ketosis during days of not attending school.
Engaging school-based caregivers in management of youth with T1D on injected insulin may decrease clinically significant ketosis and minimize acute complications of diabetes.
在青少年 1 型糖尿病(T1D)患者中,较高的血红蛋白 A1c(HbA1c)水平与糖尿病酮症酸中毒(DKA)风险增加有关。
本研究旨在探讨每日学校监督的基础胰岛素注射是否可行,以及是否降低了高 HbA1c 水平儿童和青少年发生晨酮症的风险。我们假设,监督甘精胰岛素和地特胰岛素可降低酮症风险,而地特胰岛素的作用持续时间较长,可以防止连续几天未经监督注射后发生酮症。
在 2-4 周的导入期后,接受注射治疗的 T1D 青少年(10-18 岁,HbA1c≥8.5%)被随机分配至学校监督给予地特胰岛素或甘精胰岛素治疗 4 个月。学校护士每天观察血 β-羟丁酸(BHB)和血糖检查。在 COVID 关闭期间,研究团队远程监督操作。
共分析了 28 名青少年(年龄 14.3±2.3 岁,HbA1c 11.4±1.9%,64%女性)的数据。两种基础胰岛素的学校监督注射可使接受治疗 1-4 天的参与者中血 BHB 升高的比例逐渐降低。在未监督的家庭基础胰岛素剂量后 2 天,BHB 升高(≥0.6mmol/L)的参与者比例在甘精胰岛素组高于地特胰岛素组,但 p 值较高(17.2%比 9.0%,p=0.3)。两组的 HbA1c 均未发生变化。
在有发生 DKA 高风险的 T1D 青少年中,无论基础胰岛素类型如何,每日监督长效胰岛素给药可降低后续上学日血酮水平升高的可能性。更大的样本量可能表明,地特胰岛素的作用持续时间更长,在未上学期间可提供额外的酮症保护。
让学校的护理人员参与管理接受注射胰岛素的 T1D 青少年可能会减少临床显著的酮症,并最大限度地减少糖尿病的急性并发症。